5-BrdU 是一种核苷类似物，用于检测增殖细胞并与胸苷竞争掺入 DNA。

Bromodeoxyuridine (BrdU), a nucleoside analog, are used in the detection of proliferating cells and competes with thymidine for incorporation into DNA.

In RG2 rat glioma cells, Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion. In H9 cells and BJ fibroblasts, Bromodeoxyuridine alters the cell cycle profile. [1] BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession. [2]

In rat glioma RG2 tumor model, Bromodeoxyuridine (300 mg/kg, i.p. or 0.8 mg/ml, p.o.) significantly slows tumor progression. [1]

Assays are run in the presence of 100 μM ATP using 10 μM of substrate. 30 μL PROTEIN-MIX in 25% DMSO and incubated for 15 min at room temperature. 10 μL PEPTIDE-MIX is added, the mixture is incubated for 60 min at RT and stopped by adding 180 μL 6.4% TCA (final concentration: 5%). Incorporated phosphate is measured in a scintillation counter and IC50 values are calculated using a sigmoidal curve analysis program with variable hill slope[1].

Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 μM BrdU for 24 hours, and cumulative growth curves were obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment.(Only for Reference)

59-14-3

C9H11BrN2O5

307.1

BRDU;BUdR;溴脲苷;5-溴脱氧尿嘧啶核苷;Broxuridine;Bromodeoxyuridine

Ethanol:2 mg/mL(6.5 mM)
H2O:15.4 mg/mL(50 mM)
DMSO:61 mg/mL (198.63 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years